Imagen de Portada
Código QR

Seborrheic keratosis Tx: FDA-approved Eskata is a first for this common condition.

Publicado en:Dermatology Times Vol. 39; no. 9; pp. 69 - 70
Autor principal: PALMER, WHITNEY J.
Formato: statistics Journal Article
Publicado: MJH Life Sciences Sep2018
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=131679705&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 131679705
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        01966197
        DTI
      jtl: Dermatology Times
      issn: 01966197
      maglogo: N
    pubinfo:
      dt: Sep2018
      vid: 39
      iid: 9
      pid: 54670
      pub: MJH Life Sciences
      place: Cranbury, New Jersey
    artinfo:
      ui:
        131679705
        131679705
        131679705
        131679705
      ppf: 69
      ppct: 1
      formats:
      tig:
        atl: Seborrheic keratosis Tx: FDA-approved Eskata is a first for this common condition.
      aug:
        au: PALMER, WHITNEY J.
      sug:
        subj:
          Keratosis Drug Therapy
          United States Food and Drug Administration
          Hydrogen Peroxide Therapeutic Use
          Drug Approval
          Hydrogen Peroxide Administration and Dosage
          Administration, Topical
          Hydrogen Peroxide Adverse Effects
          Treatment Outcomes
      pubtype: Trade Publication
      doctype:
        statistics
        Journal Article
      ougenre: Article
      ab:
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N